These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7662849)

  • 1. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar.
    Schall R
    Biometrics; 1995 Jun; 51(2):615-26. PubMed ID: 7662849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On population and individual bioequivalence.
    Schall R; Luus HG
    Stat Med; 1993 Jun; 12(12):1109-24. PubMed ID: 8210816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-step procedure for assessing bioequivalence in the general mixed model framework.
    Vuorinen J; Turunen J
    Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Types of bioequivalence and related statistical considerations.
    Hauck WW; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of bioequivalence using a multiplicative model.
    Chow SC; Peace KE; Shao J
    J Biopharm Stat; 1991; 1(2):193-203. PubMed ID: 1844696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On TIER method for assessment of individual bioequivalence.
    Ju HL
    J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Review and use of decision rules for bioequivalence trials].
    Nicolas P; Tod M; Petitjean O
    Therapie; 1993; 48(1):15-22. PubMed ID: 8356540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S51-8. PubMed ID: 1601532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets].
    Blume H; Ali SL; Elze M; Krämer J; Wendt G; Scholz ME
    Arzneimittelforschung; 1994 Dec; 44(12):1333-8. PubMed ID: 7848353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A method for the evaluation of individual bioequivalence.
    Endrenyi L
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of individual agreements with repeated measurements based on generalized confidence intervals.
    Quiroz J; Burdick RK
    J Biopharm Stat; 2009; 19(2):345-59. PubMed ID: 19212885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetry of the mean-variability tradeoff raises questions about the model in investigations of individual bioequivalence.
    Endrenyi L; Hao Y
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):450-7. PubMed ID: 9726700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1991 Jan; 29(1):1-8. PubMed ID: 2004861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size considerations for assessing individual bioequivalence based on the method of tolerance intervals.
    Esinhart JD; Chinchilli VM
    Int J Clin Pharmacol Ther; 1994 Jan; 32(1):26-32. PubMed ID: 8199749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
    Esinhart JD; Chinchilli VM
    J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of selection bias in estimates of relative bioavailability and intrasubject variability from bioequivalence evaluations.
    Wang Y
    J Biopharm Stat; 2000 Aug; 10(3):407-24. PubMed ID: 10959920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On confidence limits associated with Chow and Shao's joint confidence region approach for assessment of bioequivalence.
    Hsu HC; Lu HL
    J Biopharm Stat; 1997 Mar; 7(1):125-34. PubMed ID: 9056593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.